Zymeworks

$33.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Zymeworks

Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It product candidate ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.

Stock Analysis

last close $35.44
1-mo return -2.5%
3-mo return 25%
avg daily vol. 414.54T
52-week high 59.03
52-week low 24.82
market cap. $1.6B
forward pe -
annual div. -
roe -43.1%
ltg forecast -
dividend yield -
annual rev. $31M
inst own. 81.4%
baraka

Subscribe now for daily local and international financial news

Subscribe